Výsledky vyhledávání - "Christopher N. Berry"

SSR182289A, a selective and potent orally active thrombin inhibitor

Autor: Mostapha Matrougui, Paul J. Schaeffer, Zsolt Bocskei, Janine Lorrain, Jean-Marc Herbert, Christopher N. Berry, Jean-Claude Jetha, Stephen E. O'Connor, Lassalle Gilbert, Jean-Michel Altenburger, Jean-Pascal Herault, Catherine Lunven, Daniel Galtier

Publikováno v: Bioorganic & Medicinal Chemistry. 12:1713-1730

SSR182289A 1 is the result of a rational optimisation process leading to an orally active thrombin inhibitor. The struc- ture incorporates an original 2-(acetylamino)-(1,1 0 -biphenyl)-3-sulfonyl N-terminal motif, a central l-Arg surrogate carrying a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd0af41662f5d32014d52712bca347fd
https://doi.org/10.1016/j.bmc.2004.01.016

Zobrazit plný text záznamu

SSR182289A, a Novel, Orally Active Thrombin Inhibitor: In Vitro Profile and ex Vivo Anticoagulant Activity

Autor: Christopher N. Berry, Jean-Michel Altenburger, Christian Pfersdorff, Frédérique Guilbert, Stephen E. O'Connor, Catherine Lunven, Jean-Pascal Herault, Lassalle Gilbert, Alain Lalé, Jean-Marc Herbert, Catherine Lecoffre

Publikováno v: Journal of Pharmacology and Experimental Therapeutics. 303:1189-1198

SSR182289A competitively inhibits human thrombin (K(i) = 0.031 +/- 0.002 microM) and shows good selectivity with respect to other human proteases, e.g., trypsin (K(i) = 54 +/- 2 microM), factor Xa (K(i) = 167 +/- 9 microM), and factor VIIa, factor IX

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05f703bcdca057674001bd1bc0f6ea61
https://doi.org/10.1124/jpet.102.040667

Zobrazit plný text záznamu

Role of clot-associated (-derived) thrombin in cell proliferation induced by fibrin clotsin vitro

Autor: E Gandossi, C Lunven, Christopher N. Berry

Publikováno v: British Journal of Pharmacology. 129:1021-1027

Thrombin is a potent mitogenic agent. Clot-associated thrombin retains its amidolytic and pro-aggregant activity. We therefore studied the ability of fibrin clots to induce proliferation in CCL39 cells (Chinese hamster lung fibroblasts), in the absen

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::695a70cc926ee2964de683df7b7bb92f
https://doi.org/10.1038/sj.bjp.0703137

Zobrazit plný text záznamu

Anticoagulant Activity and Pharmacokinetic Properties of a Sub-cutaneously Administered Mixed Micellar Formulation of Argatroban in Experimental Animals

Autor: Nigel O. Roome, Catherine Lunven, Catherine Lecoffre, Bénédicte Roger, Nathalie Vivan, Danielle Garrigou-Gadenne, Christopher N. Berry, Pierre Lainée, Alain Rouchouse, Stephen E. O'Connor, Frederic Andre

Publikováno v: Thrombosis and Haemostasis. 84:278-285

SummaryWe have studied the anticoagulant properties of a novel mixed micellar formulation containing 14 mg/ml argatroban administered by the sub-cutaneous (s. c.) route to rats, rabbits, dogs and primates. Blood samples were taken at various times po

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::860f359921a6da832558fae9a9205075
https://doi.org/10.1055/s-0037-1614008

Zobrazit plný text záznamu

Activity of a Sub-cutaneously Administered Novel Mixed Micellar Formulation of Argatroban in Rat and Rabbit Models of Venous Thrombosis

Autor: Christopher N. Berry, Sylvette Lochot, Catherine Visconte, Denise Girard, Catherine Lecoffre

Publikováno v: Thrombosis and Haemostasis. 84:286-290

SummaryWe studied the antithrombotic activity of a mixed micellar formulation containing 14 mg/ml argatroban administered by the subcutaneous (s. c.) route in rat and rabbit models of venous thrombosis. The effects on bleeding time in the rat tail tr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2708f60b36b24001a8d0c968f8c1edb6
https://doi.org/10.1055/s-0037-1614009

Zobrazit plný text záznamu

Antithrombotic activity of a monoclonal antibody inducing the substrate form of plasminogen activator inhibitor type 1 in rat models of venous and arterial thrombosis

Autor: Christine Girardot, C. Lunven, I Lechaire, Christopher N. Berry, Stephen E. O'Connor

Publikováno v: British Journal of Pharmacology. 125:29-34

1. Elevated plasminogen activator inhibitor 1 (PAI-1) is a risk factor for thrombosis, and inhibitors of the interaction between PAI-1 and tissue plasminogen activator (t-PA) have antithrombotic and prothrombolytic activity in animals. We describe th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2d59416d601f2e86ece22479ef061a05
https://doi.org/10.1038/sj.bjp.0702030

Zobrazit plný text záznamu

Antithrombotic actions of the thrombin inhibitor, argatroban, in a canine model of coronary cyclic flow: comparison with heparin

Autor: Nicole Duval, Stephen E. O'Connor, Alain Grosset, Christopher N. Berry, C. Lunven, D.P. O'Brien

Publikováno v: British Journal of Pharmacology. 118:727-733

1. The antithrombotic action of argatroban, a synthetic thrombin inhibitor, was studied in a canine model of coronary cyclic flow having some of the characteristics of acute unstable angina. Heparin was studied as a reference anticoagulant. 2. Locali

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a9ba7a4d6c9556dc41d8789f2e4cda9
https://doi.org/10.1111/j.1476-5381.1996.tb15460.x

Zobrazit plný text záznamu

Inhibition by Argatroban, a Specific Thrombin Inhibitor, of Platelet Activation by Fibrin Clot-associated Thrombin

Autor: Catherine Lecoffre, Donogh P. O’Brien, Christiane Gauffeny, Catherine Lunven, Nigel O. Roome, Christopher N. Berry

Publikováno v: Thrombosis and Haemostasis. 75:154-169

SummaryClot-associated thrombin retains amidolytic activity, and is resistant to inhibition by heparin, but not to low molecular weight thrombin inhibitors. We show that clot-associated thrombin induces platelet aggregation, is resistant to heparin:a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f97cdec9a44b07adb3fa71e73009bd94
https://doi.org/10.1055/s-0038-1650236

Zobrazit plný text záznamu

Effects of the Synthetic Thrombin Inhibitor Argatroban on Fibrin- or Clot-Incorporated Thrombin: Comparison with Heparin and Recombinant Hirudin

Autor: Christine Girardot, Catherine Lunven, Catherine Lecoffre, Christopher N. Berry

Publikováno v: Thrombosis and Haemostasis. 72:381-386

SummaryThe inhibitory effects of argatroban on clot- or fibrin-bound human thrombin were studied using the thrombin-specific chromogenic substrate S2238 (200 μM). These effects were compared to those of recombinant hirudin (rHV2 Lys 47) and the hepa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ada866a9d2e1783cafabf9cb6b46c907
https://doi.org/10.1055/s-0038-1648875

Zobrazit plný text záznamu

Antithrombotic properties of SSR182289A, a new, orally active thrombin inhibitor

Autor: Jean-Marc Herbert, Christopher N. Berry, Paul J. Schaeffer, L. Millet, Irène Lechaire, Catherine Lunven, Janine Lorrain, C. Visconte, M. Sainte-Marie, S. E. O'Connor, S. Lochot, P. Ferrari

Publikováno v: The Journal of pharmacology and experimental therapeutics. 304(2)

N -[3-[[[(1 S )-4-(5-Amino-2-pyridinyl)-1-[[4-difluoromethylene)-1-piperidinyl]carbonyl]butyl]amino]sulfonyl][1,1′-biphenyl]-2-yl]acetamide hydrochloride (SSR182289A) is a novel, potent, and selective thrombin inhibitor. We have examined the antith

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a88f8865f70ff195cbb4893247d5838
https://pubmed.ncbi.nlm.nih.gov/12538808

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání